An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of steady-state telotristat ethyl on the pharmacokinetics (PK) of single-dose fexofenadine in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lexicon Pharmaceuticals
• Treatments: Fexofenadine; Terfenadine

Criteria

Inclusion Criteria:

• Healthy adult subjects aged ≥18 to ≤55 years of age at screening

• Body mass index ≥18.0 to ≤32.0 kg/m^2

• Acceptable vital signs at Screening: Systolic blood pressure = 90-140 mm Hg, Diastolic blood pressure = 50-90 mm Hg, Heart rate = 40-100 beats per minute

• Willingness to adhere to the restrictions outlined in the protocol

• Able to comprehend and sign the Informed Consent Form

Exclusion Criteria:

• Presence of any clinically significant physical, laboratory, or ECG finding that may interfere with the study in the opinion of the Investigator

• Use of any medications, herbal tea, energy drink, herbal products, or supplements within 14 days of Day 1

• Receipt of any investigational agent or study drug within 30 days or 5 half-lives prior to Screening

• Receipt of any protein- or antibody-based therapeutic agent within 3 months of Screening

• Prior exposure to telotristat etiprate

• Use of tobacco, smoking cessation products, or nicotine products within 3 months prior to Screening

• History of major surgery within 6 months prior to Screening

• History of any GI surgery that may induce malabsorption

• History of any serious adverse reaction or hypersensitivity to any component of fexofenadine

• History of renal disease, or significantly abnormal glomerular filtration rate (<90 mL/min as calculated using the Cockcroft-Gault equation) at Screening

• History of hepatic disease, or significantly abnormal liver function tests at Screening

• History of any clinically significant psychiatric, renal, hepatic, pancreatic, cardiovascular, neurological, endocrinologic, hematological, or GI abnormality

• History of any active infection within 14 days prior to first dosing

• History of alcohol or substance abuse within 2 years prior to Screening

• Positive hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) or positive human immunodeficiency virus antibody screens

• Concurrent conditions that could interfere with safety and/or tolerability measurements

• Donation or loss of >500 mL of blood or blood product within 3 months prior to Screening

• Women who are breastfeeding or are planning to become pregnant during the study

• Positive serum pregnancy test (females only)

• Positive urine screen for selected drugs of abuse and cotinine

• Consumption of alcohol within 48 hours prior to study start

• Consumption of caffeine- and/or xanthine-containing products within 72 hours of study start

• Consumption of grapefruit, Seville oranges, and grapefruit- or Seville orange-containing products within 72 hours prior to study start

• Unable or unwilling to communicate or cooperate with the Investigator for any reason

• Use of any drugs or substances that are known to be substrates, inducers, or inhibitors of CYP3A4 within 30 days prior to the first dose